Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q1 2019 · 10-Q
Revenue$15.98K$15.98K— vs Q1 2018 Net Income-$1.41M-$1.41MN/M vs Q1 2018 EPS Diluted-$0.07-$0.07N/M vs Q1 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
-$2,595,854
N/M
Operating Cash Flow-$1,833,755N/M Free Cash Flowderived-$1,862,255N/M Margins · derivedGross margin21.2%
Operating margin-16244.4%
Net margin-8822.7%
ended Mar 31, 2019 · filed May 20, 2019 · 50 d after period end